Form 4: Reviva Pharmaceuticals Director Acquires Stock Options

Leslie D. Funtleyder, a director at Reviva Pharmaceuticals, was granted stock options for 8,200 shares on December 10, 2024.

Summary

• Leslie D. Funtleyder, a director of Reviva Pharmaceuticals Holdings, Inc., was granted stock options to purchase 8,200 shares of common stock.
• The options were granted on December 10, 2024, with an exercise price of $2.52 per share.
• The options vest 100% on the one-year anniversary of the grant date, provided the director remains on the board.
• The options expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to directors, which is generally viewed positively as it aligns interests. There are no negative implications or surprises.

Positives

• The granting of stock options to a director aligns their interests with the company's performance and shareholder value.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants to directors are a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting period of one year is fairly typical, designed to retain directors and align their interests with the long-term success of the company.
• The exercise price being based on the closing price on the grant date is also a common practice to ensure fairness and transparency.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, director, equity, Reviva Pharmaceuticals, insider trading, beneficial ownership